	US 12,304,949 B2
	Anti-S100A4 humanized antibodies, uses and methods
Jonas Hallén, Oslo (NO); Rizwan Iqbal Hussain, Oslo (NO); Jörg Klingelhöfer, Oslo (NO); Tim Buss, Carlsbad, CA (US); and Darragh MacCann, Belfast (GB)
Assigned to Arxx Therapeutics AS, (NO)
Filed by Arxx Therapeutics AS, Oslo (NO)
Filed on Nov. 27, 2024, as Appl. No. 18/962,263.
Application 18/962,263 is a continuation of application No. 18/264,483, previously published as PCT/EP2022/053095, filed on Feb. 9, 2022.
Claims priority of provisional application 63/147,483, filed on Feb. 9, 2021.
Prior Publication US 2025/0092125 A1, Mar. 20, 2025
Int. Cl. C07K 16/24 (2006.01); A61P 35/00 (2006.01); C12N 15/63 (2006.01)

CPC C07K 16/24 (2013.01) [A61P 35/00 (2018.01); C12N 15/63 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01)]

25 Claims

1. An isolated antibody that specifically binds S100A4, the antibody comprising a heavy chain variable region (VH) comprising the heavy chain complementarity-determining region 1 (CDR-H1), CDR-H2, and CDR-H3 amino acid sequences of the VH amino acid sequences set forth in SEQ ID NO: 13; and a light chain variable region (VL) comprising the light chain complementarity-determining region 1 (CDR-L1), CDR-L2, and CDR-L3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 47, wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 13 and/or the VL comprises the amino acid sequence set forth in SEQ ID NO: 47.